54 Analytes · 7 Sub-Panels

Discovery Engine

MSD Human Biomarker 54-Plex Panel — Comprehensive Discovery Profiling

The broadest single-well multiplex immunoassay on the MSD platform: 54 biomarkers spanning cytokines, chemokines, growth factors, vascular injury markers, TH17 family cytokines, and acute-phase proteins — organized across 7 biologically coherent sub-panels, all from one 25 µL sample.

The 54-Plex is not a random collection of 54 analytes — it is a structured biomarker discovery engine organized into seven functional sub-panels that can be used together for broad profiling or individually as focused follow-up assays. This modular architecture supports a discovery-to-validation funnel: start with the full 54-plex for unbiased hypothesis generation, identify the 6–10 analytes that discriminate your groups of interest, then narrow to those specific sub-panels or custom U-PLEX configurations for validation — all on the same platform, with the same ECL detection chemistry, eliminating platform-switching variability. Published in peer-reviewed research across autoimmune disease, cardiovascular risk, metabolic syndrome, oncology, and infectious disease cohorts.

Inquire About the 54-Plex Explore the 7 Sub-Panels

Comprehensive Biomarker Discovery with the 54-Plex Panel

Traditional biomarker discovery follows a fragmented workflow: screen by ELISA one analyte at a time (consuming mL of sample), or use broad but analytically noisy bead-based panels, then validate hits on a different platform — introducing cross-platform variability at every transition. The 54-Plex consolidates this into a single platform, single sample, single run: the same ECL detection chemistry that validates your hits is the same chemistry that discovered them.

Sub-Panel Structure and Biological Rationale

The 54 analytes are not an arbitrary list — they are organized into seven functionally coherent sub-panels, each targeting a specific aspect of human biology. This modular architecture means the 54-Plex can be deployed as a complete discovery panel, or individual sub-panels can be run independently for focused follow-up — all on the same instrument platform with the same detection technology.

Proinflammatory Panel 1 (10 analytes): IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-α — the core cytokine panel for Th1/Th2/inflammatory balance
Cytokine Panel 1 (10 analytes): GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF-A — extended cytokine and growth factor coverage
Chemokine Panel 1 (10 analytes): Eotaxin, Eotaxin-3, IL-8, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC — immune cell trafficking and chemotaxis
Angiogenesis Panel 1 (7 analytes): FGF (basic), PlGF, Tie-2, VEGF-A, VEGF-C, VEGF-D, VEGFR-1/Flt-1 — vascular remodeling and angiogenic signaling
TH17 Panel 1 (7 analytes): IL-17A, IL-21, IL-22, IL-23, IL-27, IL-31, MIP-3α — autoimmune and inflammatory TH17 axis
Cytokine Panel 2 (8 analytes): IL-17A/F, IL-17B/C/D, IL-1RA, IL-3, IL-9, TSLP — additional IL-17 family members and regulatory cytokines
Vascular Injury Panel 2 (4 analytes): CRP, SAA, sICAM-1, sVCAM-1 — acute-phase proteins and endothelial activation markers

Research Applications Across Disease Areas

Because the 54-Plex spans cytokine, chemokine, angiogenic, and vascular injury pathways simultaneously, it is one of the few biomarker discovery tools applicable across multiple therapeutic areas without panel switching:

Autoimmune & inflammatory diseases — SLE, RA, IBD, psoriasis: TH17 cytokines (IL-17A, IL-21, IL-22, IL-23) + proinflammatory cytokines + chemokines + acute-phase proteins in a single run
Cardiovascular & metabolic disease — CRP, SAA, sICAM-1, sVCAM-1 + angiogenesis panel (VEGF family, Tie-2, PlGF) + inflammatory cytokines for cardiometabolic risk stratification research
Immuno-oncology — 54 analytes capturing the tumor-immune interface: checkpoint-related cytokines, chemokines driving T-cell infiltration, angiogenic factors reflecting tumor vasculature, and acute-phase proteins indicating systemic inflammatory response
Infectious disease & vaccine research — broad cytokine/chemokine profiling captures the full innate-to-adaptive immune response cascade, from early IFN responses through T-cell polarization to memory signatures
Respiratory disease — TH2 cytokines (IL-4, IL-5, IL-13), eosinophil-associated chemokines (Eotaxin family), and TSLP — key mediators of Type 2 airway inflammation — all quantified simultaneously

The 54-Plex has been used in published peer-reviewed research including a 2024 study in Communications Medicine (Nature) applying the panel to biomarker discovery in diverse disease contexts. DOI: 10.1038/s43856-024-00474-2

Panel Architecture — Seven Functional Sub-Panels

Each sub-panel targets a distinct aspect of human biology and can be used independently or as part of the complete 54-Plex.

Proinflammatory (10)

IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8/CXCL8, IL-10, IL-12p70, IL-13, TNF-α. Covers the Th1/Th2/inflammatory cytokine core — the most frequently requested cytokine panel in preclinical and clinical research. IL-6 and TNF-α span ng/mL–pg/mL range; IL-4 and IL-13 require pg/mL sensitivity for baseline quantification.

Cytokine Panel 1 (10)

GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF-A. Adds IL-17A (key TH17 effector), IL-5 (eosinophil/Type 2), IL-7 (T-cell homeostasis), and the shared IL-12/IL-23p40 subunit targeted by ustekinumab. VEGF-A bridges cytokine and angiogenesis panels.

Chemokine (10)

Eotaxin/CCL11, Eotaxin-3/CCL26, IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, MCP-4/CCL13, MDC/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, TARC/CCL17. Immune cell trafficking readout: Th1 (IP-10), monocyte/macrophage (MCP-1), eosinophil (Eotaxin family), and Th2 (MDC, TARC) chemokine axes in a single sub-panel.

Angiogenesis (7)

FGF (basic), PlGF, Tie-2, VEGF-A, VEGF-C, VEGF-D, VEGFR-1/Flt-1. VEGF family ligands + decoy receptor (sVEGFR-1) + angiopoietin receptor (Tie-2) + PlGF — captures both pro- and anti-angiogenic signaling balance. Relevant for oncology, cardiovascular, and placental/vascular research.

TH17 Panel (7)

IL-17A, IL-21, IL-22, IL-23, IL-27, IL-31, MIP-3α/CCL20. Full TH17 axis: effector cytokines (IL-17A, IL-22), TH17-polarizing (IL-23), TH17-amplifying (IL-21), regulatory (IL-27), and TH17-recruiting chemokine (MIP-3α/CCL20 — the CCR6 ligand). Key panel for autoimmune and inflammatory disease research.

Cytokine Panel 2 (8)

IL-17A/F, IL-17B, IL-17C, IL-17D, IL-1RA, IL-3, IL-9, TSLP. Completes IL-17 family coverage (all 6 members across both panels). IL-1RA (anti-inflammatory receptor antagonist). TSLP — an epithelial-derived alarmin driving Type 2 inflammation; target of tezepelumab. IL-9 — mast cell and TH9 biology.

Vascular Injury (4)

CRP, SAA, sICAM-1, sVCAM-1. Acute-phase reactants (CRP, SAA) + endothelial adhesion molecules (sICAM-1, sVCAM-1). CRP spans ng/mL–µg/mL — ECL's wide dynamic range accommodates this without dilution. SAA is the most dynamically responsive acute-phase protein (1,000-fold induction).

Discovery-to-Validation Workflow on a Single Platform

The 54-Plex's modular sub-panel architecture enables a seamless biomarker workflow that eliminates platform-switching variability.

Discovery Phase

Run the full 54-Plex on a representative subset of your cohort. Identify the 6–15 analytes that show the strongest group discrimination, largest fold-change, or most consistent trajectory — without pre-selection bias. Single 25 µL sample per timepoint.

Refinement Phase

Narrow to the 1–2 sub-panels containing your analytes of interest, or design a focused U-PLEX custom panel with only the confirmed targets. Same ECL detection chemistry — no cross-platform recalibration. Reduced cost per sample for larger cohorts.

Validation Phase

Run the focused panel on your full cohort for statistical validation. If ultra-high sensitivity is needed for specific low-abundance hits, deploy S-PLEX single-plex assays on the same sample set. All data generated on one instrument family — analytically continuous from discovery to publication.

This funnel approach is cited as best practice in the biomarker literature: broad, unbiased discovery followed by targeted, analytically focused validation — without the platform-switching variability that introduces batch effects between discovery and confirmation phases.

Additional Multiplex Configurations — Human, Mouse & NHP

Beyond the 54-Plex, additional pre-configured biomarker discovery panels are available across species and plex levels — from focused 29-plex mouse panels to the comprehensive 71-plex human platform.

Panel	Plex	Species	Coverage
Human Biomarker 40-Plex	40	Human	Cytokines, chemokines, vascular markers (CRP, SAA, ICAM-1, VCAM-1), angiogenic factors (VEGF-A/C/D, PlGF, Tie-2, FGF basic, VEGFR-1)
Human Biomarker 44-Plex	44	Human	Extended IL-17 family (IL-17A/F/B/C/D) + TSLP + IL-3 + IL-9 + full cytokine/chemokine coverage
Human Biomarker 46-Plex	46	Human	44-Plex + VEGF-D, VEGF-C, SAA, PlGF — adding angiogenic and vascular dimensions
Human Biomarker 71-Plex	71	Human	Full-spectrum: cytokines, chemokines (CXCL + CCL families including MCP-1/2/3/4, MIP-3α/β), growth factors (EPO, TPO, FLT3L, M-CSF, G-CSF), interferons (IFN-α2a, IFN-β, IFN-λ1), IL-1 family, TRAIL, YKL-40, MIF
Mouse Biomarker 29-Plex	29	Mouse	Cytokines + chemokines (KC/GRO, IP-10, MCP-1, MIP-1α, MIP-2, MIP-3α) + IL-17 family + IL-27p28, IL-31, IL-33
Mouse Biomarker 35-Plex	35	Mouse	29-Plex + GM-CSF, VEGF-A, EPO, IL-12/IL-23p40, MIP-1β
Mouse Biomarker 50-Plex	50	Mouse	35-Plex + interferons (IFN-α, IFN-β), matrix (MMP-9), chemokine receptors (6CKine/CCL21, BCA-1/BLC, RANTES), BAFF, CD40, TNFRI, NGAL
NHP Biomarker 61-Plex	61	NHP	Full cytokine/chemokine/growth factor coverage + interferons + IL-2Rα + TRAIL + YKL-40 — translational NHP biomarker discovery

All panels share the same ECL detection platform and 25 µL sample requirement. Panel selection depends on species, plex coverage needed, and specific analyte requirements. Contact our scientific team for analyte-level comparison across configurations. All services are for research use only.

ECL Detection for High-Density Biomarker Panels

Why electrochemiluminescence is uniquely suited for high-density biomarker panels spanning wide concentration ranges.

Analytical Requirements for 54-Analyte Multiplexing

The 54-Plex spans an extraordinary concentration range: CRP and SAA at µg/mL during acute inflammation sit alongside IL-4 and IL-5 at sub-pg/mL in the same well. This is analytically demanding — a platform must maintain precision at both extremes without dilution compromises. Fluorescence-based multiplexing at this density introduces spectral overlap artifacts that disproportionately affect low-abundance targets. ECL's spatial electrode addressing resolves this by giving each analyte an independent, cross-talk-free signal channel.

V-PLEX Lot Control for Multi-Year Studies

The 54-Plex is a V-PLEX product: manufacturer-pre-coated plates with lot-controlled reagents and documented lot-to-lot bridging. For multi-year biomarker discovery programs — where samples are collected, analyzed, and re-analyzed across years — this lot traceability ensures that a cytokine value measured in Year 1 is analytically comparable to one measured in Year 3, even if reagent lots have changed. Lot-specific calibrator concentrations, QC acceptance ranges, and bridging factors are documented in each panel datasheet.

54-Plex Service Details

Service Package

Item	Full Service	Kit Only
Sample Processing	Included	— Self-run
54-Analyte Standard Curves	8-point, all 54 analytes	Calibrators provided
QC Samples	3 levels per sub-panel	— User-prepared
Full 54-Analyte Report	Organized by sub-panel	— Self-analysis
Discovery Consultation	Sub-panel refinement advice	— Not included

For Research Use Only. Not for diagnostic procedures.

How to Get Started

Consult

Describe your disease area and study design. We'll advise whether the full 54-Plex, specific sub-panels, or a custom U-PLEX configuration best serves your discovery objectives.

Ship

Send samples on dry ice. 25 µL per well — the full 54 analytes from less sample than a single ELISA well. Pre-analytical guidance specific to your matrix provided.

Discover & Refine

Receive your 54-plex discovery dataset organized by sub-panel. We'll help identify the discriminating analytes and plan the focused validation phase — all on the same platform.

Disease Area Applications

Cardiometabolic

CRP + SAA + sICAM-1 + sVCAM-1 + VEGF family + Tie-2 + inflammatory cytokines — cardiovascular risk, atherosclerosis, and metabolic syndrome biomarker panels covered in a single well.

Autoimmune

Full TH17 axis (7 cytokines) + Th1/Th2 balance (10 proinflammatory) + chemokine trafficking (10 chemokines) + acute-phase (CRP, SAA) — comprehensive autoimmune disease profiling.

Immuno-Oncology

54 analytes spanning the tumor-immune interface: cytokines, chemokines driving T-cell infiltration, angiogenic factors, and systemic inflammatory markers. Discovery panel for IO biomarker programs.

Infectious Disease

Captures the full innate-to-adaptive immune cascade: early IFN/cytokine responses → chemokine-mediated immune recruitment → T-cell polarization → acute-phase resolution. Vaccine and adjuvant research.

Respiratory

Type 2 inflammation markers: IL-4, IL-5, IL-13, TSLP + Eotaxin family (eosinophil chemokines) + mucus/remodeling cytokines (IL-9, IL-22) + inflammatory control (IL-10, IL-1RA).

Metabolic & Obesity

Adipose-derived inflammatory mediators (IL-6, TNF-α, IL-1β) + insulin-resistance-associated cytokines + vascular markers (sICAM-1, sVCAM-1) + acute-phase proteins (CRP, SAA).

54-Plex Frequently Asked Questions

Is the 54-Plex suitable as a first-pass discovery tool, or should I start with a smaller panel?

The 54-Plex is specifically designed as a discovery engine — its value lies in the breadth of unbiased coverage. Starting with a focused 10-plex means pre-selecting which analytes to measure, potentially missing unexpected biomarkers. The recommended workflow: run the 54-Plex on a subset of samples for discovery → identify discriminating analytes → narrow to focused sub-panels or custom U-PLEX for validation. This approach is cost-efficient because the discovery phase uses fewer samples, while the validation phase uses a cheaper focused panel on the full cohort. Our scientific team can help design the sampling strategy for each phase.

Can I run only specific sub-panels instead of the full 54-Plex?

Yes. The 54-Plex can be run as the complete 7-sub-panel set or as individual sub-panels. For example, if your research focuses on cardiovascular biomarkers, you might run the Angiogenesis Panel (7 analytes) + Vascular Injury Panel (4 analytes) + Proinflammatory Panel (10 analytes) — 21 analytes total — rather than the full 54. During project consultation, we'll help determine which sub-panel combination provides optimal coverage for your research questions while managing cost efficiency.

How do you handle the extreme concentration range — CRP at µg/mL alongside IL-4 at pg/mL?

This is one of ECL's core advantages over fluorescent multiplexing. Electrochemiluminescence provides 4–5 log dynamic range per analyte — sufficient to accommodate CRP at µg/mL and IL-4 at pg/mL in the same well. Additionally, the 54-Plex's 7-sub-panel architecture means each sub-panel can be optimized for its expected concentration range independently. In practice, the ECL signal is linear across the full range without requiring the dilution adjustments or sensitivity compromises that narrower-range platforms require. Spiked recovery and dilution linearity are verified across the concentration range for each analyte.

How many samples do I need for a statistically meaningful 54-Plex discovery study?

This depends on your study design, effect sizes, and the number of group comparisons, but as a general framework: discovery phase typically requires 20–50 samples per group to identify candidate biomarkers with moderate-to-large effect sizes. Because the 54-Plex measures 54 analytes simultaneously, multiple testing correction (e.g., Benjamini-Hochberg) should be applied — our data reports include both raw and adjusted p-values. Validation phase with a focused panel typically requires larger cohorts (powered for the effect sizes observed in discovery). Our scientific team can provide statistical consultation on sample size estimation based on your specific study parameters and expected effect sizes from published literature.

What sample types are compatible with the 54-Plex, and are there analyte-specific stability concerns?

The 54-Plex is validated for serum and EDTA plasma as primary matrices; CSF and cell culture supernatant can be accommodated on consultation. Because the panel spans multiple protein families, pre-analytical stability varies by analyte class: cytokines are susceptible to freeze-thaw degradation (single-use aliquots recommended); CRP and SAA are relatively stable; complement factors may be affected by repeated freeze-thaw. We provide analyte-specific stability guidance during study design. General recommendation: EDTA plasma, processed within 1 hour of collection, single-use aliquots, −80°C storage, ship on dry ice. Consistent pre-analytical handling across all samples within a study is the single most important factor for robust 54-Plex data.

Inquiry Basket